{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T17:05:36Z","timestamp":1765818336339,"version":"3.48.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jhep.2025.10.021","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T14:51:32Z","timestamp":1763650292000},"page":"231-232","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The identification of interleukin-27 as one key player in restoring virus-specific T-cell dysfunction in chronic hepatitis B virus infection"],"prefix":"10.1016","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4425-2640","authenticated-orcid":false,"given":"Lisa","family":"Sandmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"journal-title":"J Hepatol","article-title":"EASL Clinical Practice Guidelines on the management of hepatitis B virus infection","year":"2025","key":"10.1016\/j.jhep.2025.10.021_bib1"},{"issue":"1","key":"10.1016\/j.jhep.2025.10.021_bib2","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jhep.2025.03.024","article-title":"Toward functional cure of hepatitis B: is combination therapy the key?","volume":"83","author":"Sandmann","year":"2025","journal-title":"J Hepatol"},{"issue":"1 Suppl","key":"10.1016\/j.jhep.2025.10.021_bib3","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.jhep.2016.01.026","article-title":"Adaptive immunity in HBV infection","volume":"64","author":"Bertoletti","year":"2016","journal-title":"J Hepatol"},{"issue":"7777","key":"10.1016\/j.jhep.2025.10.021_bib4","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41586-019-1620-6","article-title":"Dynamics and genomic landscape of CD8(+) T cells undergoing hepatic priming","volume":"574","author":"Benechet","year":"2019","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.jhep.2025.10.021_bib5","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1038\/s41590-025-02199-3","article-title":"CD4(+) T cells license Kupffer cells to reverse CD8(+) T cell dysfunction induced by hepatocellular priming","volume":"26","author":"Venzin","year":"2025","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jhep.2025.10.021_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.902853","article-title":"Antiviral activities of interleukin-27: a partner for interferons?","volume":"13","author":"Amsden","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhep.2025.10.021_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1395921","article-title":"IL-27 expression regulation and its effects on adaptive immunity against viruses","volume":"15","author":"Andres-Martin","year":"2024","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.jhep.2025.10.021_bib8","doi-asserted-by":"crossref","first-page":"691","DOI":"10.4049\/jimmunol.1300252","article-title":"IL-27, a cytokine, and IFN-lambda1, a type III IFN, are coordinated to regulate virus replication through type I IFN","volume":"192","author":"Cao","year":"2014","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.jhep.2025.10.021_bib9","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/cmi.2016.67","article-title":"Type I IFN augments IL-27-dependent TRIM25 expression to inhibit HBV replication","volume":"15","author":"Tan","year":"2018","journal-title":"Cell Mol Immunol"},{"issue":"4","key":"10.1016\/j.jhep.2025.10.021_bib10","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/ni.1996","article-title":"CD4+ T cell help and innate-derived IL-27 induce Blimp-1-dependent IL-10 production by antiviral CTLs","volume":"12","author":"Sun","year":"2011","journal-title":"Nat Immunol"},{"issue":"4","key":"10.1016\/j.jhep.2025.10.021_bib11","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1002\/hep.26166","article-title":"High susceptibility to liver injury in IL-27 p28 conditional knockout mice involves intrinsic interferon-gamma dysregulation of CD4+ T cells","volume":"57","author":"Zhang","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.10.021_bib12","article-title":"IL-21-Deficient T follicular helper cells support B cell responses through IL-27 in patients with chronic hepatitis B","volume":"11","author":"Khanam","year":"2020","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.jhep.2025.10.021_bib13","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1111\/liv.13372","article-title":"The role of interleukin-27 in predicting spontaneous HBeAg seroconversion in chronic hepatitis B infection","volume":"37","author":"Li","year":"2017","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.jhep.2025.10.021_bib14","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.clim.2008.10.011","article-title":"Hepatitis B virus enhances interleukin-27 expression both in vivo and in vitro","volume":"131","author":"Zhu","year":"2009","journal-title":"Clin Immunol"},{"issue":"8055","key":"10.1016\/j.jhep.2025.10.021_bib15","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/s41586-024-08510-w","article-title":"IL-27 elicits a cytotoxic CD8(+) T cell program to enforce tumour control","volume":"639","author":"Breart","year":"2025","journal-title":"Nature"},{"issue":"4_suppl","key":"10.1016\/j.jhep.2025.10.021_bib16","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2025.43.4_suppl.605","volume":"43","author":"Li","year":"2025","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.jhep.2025.10.021_bib17","article-title":"A randomized phase 2 study of casdozokitug, an IL-27 targeting antibody, in combination with toripalimab plus bevacizumab in patients with unresectable and\/or locally advanced or metastatic hepatocellular carcinoma","volume":"43","author":"Li","year":"2025","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.jhep.2025.10.021_bib18","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1158\/2159-8290.CD-20-1628","article-title":"IL27 signaling serves as an immunologic checkpoint for innate cytotoxic cells to promote hepatocellular carcinoma","volume":"12","author":"Aghayev","year":"2022","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.jhep.2025.10.021_bib19","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/1055-9965.EPI-20-1081","article-title":"Serum IL27 in relation to risk of hepatocellular carcinoma in two nested case-control studies","volume":"30","author":"Yuan","year":"2021","journal-title":"Cancer Epidemiol Biomarkers Prev"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827825026042?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827825026042?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T17:02:56Z","timestamp":1765818176000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827825026042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0168827825026042"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2025.10.021","relation":{},"ISSN":["0168-8278"],"issn-type":[{"type":"print","value":"0168-8278"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The identification of interleukin-27 as one key player in restoring virus-specific T-cell dysfunction in chronic hepatitis B virus infection","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2025.10.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association for the Study of the Liver. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}